期刊文献+

抗线粒体-M_2抗体在原发性胆汁性肝硬化的意义 被引量:3

The Significance of Antimitochondria Antibody-M_2 Subtype (AMA-M_2) to Primary Biliary Cirrhosis(PBC)
下载PDF
导出
摘要 目的 探讨抗线粒体抗体 - M2 亚型 ( AMM- M2 )对原发性胆汁性肝硬化 ( PBC)的意义。方法 应用酶免疫斑点法 ( DIBA)检测抗 AMA- M2 抗体 1 63例 ,M2 抗原包被区出现深蓝或紫色条带为阳性 ,无颜色为阴性。结果 PBC患者 39例 ,AMA- M2 抗体 38例阳性 ,阳性率 97.4% ;自身免疫性肝炎患者 1 6例 ,AMA- M2 抗体 1例阳性 ,阳性率为 6.3% ;慢性乙型肝炎、系统性红斑狼疮和正常对照组均阴性。 PBC患者 AMA- M2 抗体阳性率明显高于其它组 ( P<0 .0 1 )。该法灵敏度为 97.4% ,特异性为 98.9%。结论 DI-BA检测 AMA- M2 抗体灵敏度高 ,特异性强 ,可作为 PBC重要的血清学指标 ,同时结合临床症状、生化检查、肝组织活检等提高 PBC的诊断率。 Objective To study diagnosis significance of antimitochondria antibody-M 2 subtype (AMA-M 2) to primary biliary cirrhosis(PBC).Methods Using DIBA to detect AMA-M 2 of 163 cases.It was positive when the coating area of M 2 antigen showed blue or purple strap and negative with no color.Results 39 cases were the patients with PBC,and 38 cases were the patients with positive AMA-M 2.The positive rate was 97.4%.16 cases were the patients with autoimmune hepatitis and only one case was the patient with positive AMA-M 2 .The positive rate was 6.3%.Chronic Hepatitis B group,systemic lupus erythematosus(SLE) group and normal matched contol group were all negative AMA-M 2.The positive rate of AMA-M 2 of PBC patients was much higher than that of other groups (P<0.01) .The susceptibility of this method was 97.4%.The specificity was 98.9%.Conclusion The method of detecting AMA-M 2 by DIBA has higher susceptibility and better specificity.So AMA-M 2 can be an important serology mark.Positive AMA-M 2 with clinical symptom,biochemistry examination,liver biopsy can enhance the diagnosis rate of PBC.
出处 《现代检验医学杂志》 CAS 2004年第1期38-39,共2页 Journal of Modern Laboratory Medicine
关键词 原发性胆汁性肝硬化 抗线粒体抗体-M2 亚型 酶免疫斑点法 primary biliary cirrhosis(PBC) antimitochondria antibody-M 2 subtype
  • 相关文献

参考文献10

  • 1[1]Walker JG,Doniach D,Roitt IM,et al. Serological tests in the diagnosis of primary cirrhosis[J]. Lancet, 1965:827~830.
  • 2[2]Neuberger J. Primary biliary cirrhosis[J]. Lancet, 1997;350:875~879.
  • 3[3]Heathcote EJ. Management of primary biliary cirrhosis. The American association for the study of liver diseases practice guidelines [J ]. Hepatology, 2000; 31:1005 ~ 1013.
  • 4[4]Lindor KD. Primary biliary cirrhosis:questions and promises[J]. Ann Intern Med, 1997; 126: 733~ 735.
  • 5[5]Neuberger J,Thomson R. PBC and AMA-what is the connection? [J]. Hepatology,1999;29:271~276.
  • 6[6]Fussey S,Guest JR,James O,et al. Identification and analysis of the major M autoantigens in primary biliary cirrhosis[J].Proc Natl Acad Sci USA, 1988; 85 : 8654 ~ 8658.
  • 7[7]Klein R,Berg PA. Significance of antimitochondrial antibody profiles in primary biliary cirrhosis. In:Lindon KD,Heathcote EJ, Poupon R, eds. Primary biliary cirrhosis: From pathogenesis to clinical treatment [M]. Dordrecht, Netherland, Kluser Academic Pub, 1998: 24 ~ 34.
  • 8[8]Bassendine MF,Jones DE,Yeaman SJ. Biochemistry and autoimmune response to the 2-oxyacid dehydrogenase complexes in primary biliary cirrhosis [J]. Sernin Liver Dis, 1997;17:49~60.
  • 9[9]Sherlock S. Dooley J. Diseases of the liver and biliary system[M]. 11 th ed. Oxford UK, Blackwell Science, 2002 : 242.
  • 10[10]Zein CO. Boe GM. Donlinger J. et al. The role of liver biopsy in diagnosis of primary biliary cirrhosis [J]. Hepatology,2001; 34: 343.

同被引文献36

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部